Advertisement
INSM vs VRTX
Which Stock Would AI Choose? Insmed Incorporated (INSM) vs. Vertex Pharmaceuticals Incorporated (VRTX) Stock Comparison
Key Takeaways
- Insmed (INSM) has delivered over 90% one-year returns driven by strong revenue growth from ARIKAYCE and BRINSUPRI launches, contrasting Vertex's (VRTX) more modest 8-10% yearly gains from its established cystic fibrosis franchise.
- INSM trades at a market cap of approximately $33 billion with 2025 revenue of $606 million (up 67% YoY), while VRTX boasts $115 billion market cap and $12 billion revenue (up 9% YoY).
- Recent momentum favors INSM with positive Phase 3b ENCORE data for ARIKAYCE supporting label expansion, versus VRTX's pipeline advances in povetacicept for IgA nephropathy.
- Analyst targets average $210+ for INSM (Strong Buy consensus) and $550 for VRTX (Moderate Buy), implying significant upside for both amid biotech volatility.
- INSM exhibits higher beta (1.17) reflecting riskier rare disease focus, while VRTX offers stability with lower beta around 0.3.
Introduction
Insmed Incorporated (INSM) and Vertex Pharmaceuticals Incorporated (VRTX) represent compelling biotech plays in the healthcare sector, focusing on therapies for serious respiratory and genetic diseases. INSM targets rare pulmonary infections with high-growth potential from recent approvals, while VRTX dominates cystic fibrosis (CF) treatment with a mature portfolio expanding into pain and renal indications. Traders seeking momentum in volatile biotech names and investors prioritizing stable revenue growth will find this stock comparison valuable for assessing relative performance, pipeline catalysts, and market positioning in the current environment.
INSM Overview and Recent Performance
Insmed Incorporated (INSM), a global biopharmaceutical firm, specializes in therapies for rare diseases, particularly nontuberculous mycobacterial (NTM) lung infections and bronchiectasis. Its flagship products include ARIKAYCE (amikacin liposome inhalation suspension) for refractory MAC lung disease and BRINSUPRI (brensocatib), a DPP1 (dipeptidyl peptidase 1) inhibitor approved for non-CF bronchiectasis. In recent market activity, INSM shares have shown volatility but strong yearly gains exceeding 90%, trading around $153 with a $33 billion market cap. Full-year 2025 revenue hit $606 million, up 67% YoY, fueled by BRINSUPRI's ramp-up and ARIKAYCE growth. Sentiment has improved with positive topline from the Phase 3b ENCORE study of ARIKAYCE in newly diagnosed MAC patients, meeting endpoints and fulfilling FDA post-marketing requirements for potential label expansion and traditional approval filing in H2 2026. Analyst upgrades, including Morgan Stanley's 28% price target hike, underscore optimism despite YTD dips and pipeline setbacks like the discontinued CRSsNP program.
VRTX Overview and Recent Performance
Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology leader focused on transformative therapies for serious diseases, anchored by its cystic fibrosis portfolio including TRIKAFTA, ALYFTREK, and others addressing CFTR mutations. The company is diversifying into sickle cell disease (via CASGEVY), acute pain (JOURNAVX/suzetrigine), and renal conditions. Recently, VRTX shares have experienced pressure, down about 9% over the past year but up modestly YTD, trading near $443 with a $113 billion market cap. Q4 2025 revenue rose 10% to $3.19 billion, contributing to full-year $12 billion (up 9% YoY), driven by CF franchise strength and non-CF contributions exceeding $500 million. Positive developments include Week 36 interim data from the RAINIER Phase 3 trial of povetacicept in IgA nephropathy (IgAN), showing 52% proteinuria reduction, supporting a BLA filing for accelerated approval in H1 2026. JOURNAVX data in pain management further bolsters sentiment, though recent monthly declines reflect broader biotech trends.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, handpicked from over 351 total bots that trade thousands of tickers across stocks, ETFs, and crypto. Only 25 bots earn a spot in this trending section based on their adaptability to current market conditions, featuring diverse strategies like momentum, sector rotation, technical patterns, and fundamental analysis. Timeframes range from 5-minute scalping to 60-minute swings, with volatility filters (low, medium, high) and risk management tools. Standout performers boast annualized returns up to +227%, win rates of 70-95%, and profit factors exceeding 3.0, such as bots achieving 86% wins on leveraged ETFs or 90% on sector plays. These bots employ AI agents for real-time signals, virtual portfolios, and brokerage execution, enabling copy trading without minimum balances. Explore Tickeron’s Trending AI Robots to identify tools suited to your style and market outlook.
Head-to-Head Comparison
Insmed (INSM) pursues a high-risk, high-reward model in niche rare pulmonary diseases, contrasting Vertex's (VRTX) established CF dominance with diversification into gene-editing (CASGEVY) and non-CF areas like pain and kidneys. Growth drivers for INSM center on commercial ramps for ARIKAYCE/BRINSUPRI targeting $1B+ peak sales, versus VRTX's steady 9-10% CF revenue plus $500M+ from new launches. Recent momentum tilts to INSM (YTD -12% but +97% 1Y) amid ENCORE success, while VRTX (-3% YTD, -9% 1Y) gains from renal catalysts but faces CF peak concerns. Risk factors include INSM's clinical volatility (beta 1.17, losses) versus VRTX's profitability (beta 0.3, 34% margins). Both share biotech sector exposure, but VRTX offers broader resilience; sentiment favors INSM's upside in rallies.
Tickeron AI Verdict
Tickeron’s AI currently favors INSM due to superior trend consistency from revenue hyper-growth, recent ENCORE catalysts, and stronger relative one-year momentum positioning it ahead in biotech recovery plays. VRTX trails with stable but slower growth and recent price softness, though its pipeline offers probabilistic balance for conservative positioning. Observable factors like INSM's 90%+ returns tip near-term edge toward higher volatility upside.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INSM is a Buy and VRTX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INSM’s FA Score shows that 1 FA rating(s) are green whileVRTX’s FA Score has 0 green FA rating(s).
- INSM’s FA Score: 1 green, 4 red.
- VRTX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INSM’s TA Score shows that 5 TA indicator(s) are bullish while VRTX’s TA Score has 3 bullish TA indicator(s).
- INSM’s TA Score: 5 bullish, 5 bearish.
- VRTX’s TA Score: 3 bullish, 6 bearish.
Price Growth
INSM (@Biotechnology) experienced а -4.69% price change this week, while VRTX (@Biotechnology) price change was -0.56% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.04%. For the same industry, the average monthly price growth was -3.95%, and the average quarterly price growth was +5.21%.
Reported Earning Dates
INSM is expected to report earnings on Apr 30, 2026.
VRTX is expected to report earnings on May 04, 2026.
Industries' Descriptions
@Biotechnology (+1.04% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| INSM | VRTX | INSM / VRTX | |
| Capitalization | 33.4B | 111B | 30% |
| EBITDA | -1.18B | 4.87B | -24% |
| Gain YTD | -11.049 | -3.770 | 293% |
| P/E Ratio | N/A | 28.48 | - |
| Revenue | 606M | 12B | 5% |
| Total Cash | 1.43B | 6.61B | 22% |
| Total Debt | 587M | 2.03B | 29% |
INSM | VRTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 67 | 4 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 78 Overvalued | 80 Overvalued | |
PROFIT vs RISK RATING 1..100 | 33 | 35 | |
SMR RATING 1..100 | 100 | 39 | |
PRICE GROWTH RATING 1..100 | 42 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 54 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INSM's Valuation (78) in the Biotechnology industry is in the same range as VRTX (80). This means that INSM’s stock grew similarly to VRTX’s over the last 12 months.
INSM's Profit vs Risk Rating (33) in the Biotechnology industry is in the same range as VRTX (35). This means that INSM’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for INSM (100). This means that VRTX’s stock grew somewhat faster than INSM’s over the last 12 months.
INSM's Price Growth Rating (42) in the Biotechnology industry is in the same range as VRTX (60). This means that INSM’s stock grew similarly to VRTX’s over the last 12 months.
VRTX's P/E Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for INSM (100). This means that VRTX’s stock grew somewhat faster than INSM’s over the last 12 months.
| INSM | VRTX | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 1 day ago 76% | 1 day ago 61% |
| Momentum ODDS (%) | 1 day ago 83% | 1 day ago 45% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 48% |
| TrendWeek ODDS (%) | 1 day ago 73% | 1 day ago 42% |
| TrendMonth ODDS (%) | 1 day ago 74% | 1 day ago 37% |
| Advances ODDS (%) | 11 days ago 71% | 3 days ago 62% |
| Declines ODDS (%) | 1 day ago 73% | 5 days ago 42% |
| BollingerBands ODDS (%) | 1 day ago 73% | 5 days ago 74% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 28% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| EMXC | 85.08 | 0.43 | +0.51% |
| iShares MSCI Emerging Mkts ex China ETF | |||
| KOKU | 116.99 | N/A | N/A |
| Xtrackers MSCI Kokusai Equity ETF | |||
| ZTWO | 50.54 | N/A | N/A |
| F/M 2-Yr Invmt Grd Corp Bd ETF | |||
| GRX | 9.19 | -0.03 | -0.33% |
| Gabelli Healthcare & Wellness Trust (The) | |||
| SMAP | 25.53 | -0.12 | -0.45% |
| Amplify Small-Mid Cap Equity ETF | |||
INSM and
Correlation & Price change
A.I.dvisor indicates that over the last year, INSM has been closely correlated with CNTN. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then CNTN could also see price increases.
| Ticker / NAME | Correlation To INSM | 1D Price Change % | ||
|---|---|---|---|---|
| INSM | 100% | -3.00% | ||
| CNTN - INSM | 74% Closely correlated | -12.21% | ||
| AXON - INSM | 40% Loosely correlated | -1.53% | ||
| ARRY - INSM | 40% Loosely correlated | -0.69% | ||
| RAPT - INSM | 37% Loosely correlated | N/A | ||
| VRDN - INSM | 37% Loosely correlated | -2.80% | ||
More | ||||